Biohaven Licenses IgG Degraders to Ono Pharma for Japan, Select Asian Markets

Biohaven entered an exclusive IgG degrader licensing agreement with Ono Pharma covering Japan, South Korea, Taiwan and ASEAN countries. Payments include USD 80 million upfront and USD 20 million upon a milestone anticipated within a year. Ono will pay royalties of approximately 20% on net sales in the licensed territory. Lead candidate BHV-1300 is in Phase 3 development for Graves' disease; the agreement also covers next-generation IgG degraders. All rights outside the licensed territory are retained, including in the United States, Europe and China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001935979-26-000080), on October 15, 2026, and is solely responsible for the information contained therein. (C) Copy